Cetuximab and anemia prevention in head and neck cancer patients undergoing radiotherapy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Cetuximab and anemia prevention in head and neck cancer patients undergoing radiotherapy ; volume:22 ; number:1 ; day:7 ; month:6 ; year:2022 ; pages:1-10 ; date:12.2022
BMC cancer ; 22, Heft 1 (7.6.2022), 1-10, 12.2022
- Urheber
-
Maahs, Lucas
Ghanem, Ahmed I.
Gutta, Radhika
Tang, Amy
Arya, Swarn
Saheli, Zaid Al
Ali, Haythem
Chang, Steven
Tam, Samantha
Wu, Vivian
Siddiqui, Farzan
Sheqwara, Jawad
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-022-09708-9
- URN
-
urn:nbn:de:101:1-2022080421312682437994
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 15.08.2025, 07:36 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Maahs, Lucas
- Ghanem, Ahmed I.
- Gutta, Radhika
- Tang, Amy
- Arya, Swarn
- Saheli, Zaid Al
- Ali, Haythem
- Chang, Steven
- Tam, Samantha
- Wu, Vivian
- Siddiqui, Farzan
- Sheqwara, Jawad
- SpringerLink (Online service)
Ähnliche Objekte (12)
Radiolabeling of anti-EGFR antibody, Cetuximab, overcomes the radiotherapy resistance of Cetuximab resistant head and neck cancer cells
Nursing care to patients with head and neck cancer undergoing radiotherapy
Nursing care to patients with head and neck cancer undergoing radiotherapy
Severe skin reaction secondary to concomitant radiotherapy plus cetuximab
Evaluating predictive factors for toxicities experienced by head & neck cancer patients undergoing radiotherapy
Erythropoietin for Prevention or Treatment of anemia in Cancer Patients Undergoing Radiotherapy; Time to Pause and think!
A prospective real-world multi-center study to evaluate progression-free and overall survival of radiotherapy with cetuximab and platinum-based chemotherapy with cetuximab in locally recurrent head and neck cancer
A Prospective Real-World Multi-Center Study to Evaluate Progression-Free and Overall Survival of Radiotherapy with Cetuximab and Platinum-Based Chemotherapy with Cetuximab in Locally Recurrent Head and Neck Cancer
Incidence of pneumonia and risk factors among patients with head and neck cancer undergoing radiotherapy
Differentiation of irradiation and cetuximab induced skin reactions in patients with locally advanced head and neck cancer undergoing radioimmunotherapy: the HICARE protocol (Head and neck cancer: ImmunoChemo and Radiotherapy with Erbitux) – a multicenter phase IV trial
Impact of cetuximab plus cisplatin alone and cetuximab plus cisplatin and paclitaxel regimen on humanistic outcome in head and neck cancer
Dysphagia therapy for head and neck cancer patients undergoing radiotherapy by speech-language pathologists in Malaysia
Radiolabeling of anti-EGFR antibody, Cetuximab, overcomes the radiotherapy resistance of Cetuximab resistant head and neck cancer cells
Nursing care to patients with head and neck cancer undergoing radiotherapy
Nursing care to patients with head and neck cancer undergoing radiotherapy
Severe skin reaction secondary to concomitant radiotherapy plus cetuximab
Evaluating predictive factors for toxicities experienced by head & neck cancer patients undergoing radiotherapy
Erythropoietin for Prevention or Treatment of anemia in Cancer Patients Undergoing Radiotherapy; Time to Pause and think!
A prospective real-world multi-center study to evaluate progression-free and overall survival of radiotherapy with cetuximab and platinum-based chemotherapy with cetuximab in locally recurrent head and neck cancer
A Prospective Real-World Multi-Center Study to Evaluate Progression-Free and Overall Survival of Radiotherapy with Cetuximab and Platinum-Based Chemotherapy with Cetuximab in Locally Recurrent Head and Neck Cancer
Incidence of pneumonia and risk factors among patients with head and neck cancer undergoing radiotherapy
Differentiation of irradiation and cetuximab induced skin reactions in patients with locally advanced head and neck cancer undergoing radioimmunotherapy: the HICARE protocol (Head and neck cancer: ImmunoChemo and Radiotherapy with Erbitux) – a multicenter phase IV trial
Impact of cetuximab plus cisplatin alone and cetuximab plus cisplatin and paclitaxel regimen on humanistic outcome in head and neck cancer
Dysphagia therapy for head and neck cancer patients undergoing radiotherapy by speech-language pathologists in Malaysia
Radiolabeling of anti-EGFR antibody, Cetuximab, overcomes the radiotherapy resistance of Cetuximab resistant head and neck cancer cells
Nursing care to patients with head and neck cancer undergoing radiotherapy
Nursing care to patients with head and neck cancer undergoing radiotherapy
Severe skin reaction secondary to concomitant radiotherapy plus cetuximab
Evaluating predictive factors for toxicities experienced by head & neck cancer patients undergoing radiotherapy
Erythropoietin for Prevention or Treatment of anemia in Cancer Patients Undergoing Radiotherapy; Time to Pause and think!
A prospective real-world multi-center study to evaluate progression-free and overall survival of radiotherapy with cetuximab and platinum-based chemotherapy with cetuximab in locally recurrent head and neck cancer
A Prospective Real-World Multi-Center Study to Evaluate Progression-Free and Overall Survival of Radiotherapy with Cetuximab and Platinum-Based Chemotherapy with Cetuximab in Locally Recurrent Head and Neck Cancer
Incidence of pneumonia and risk factors among patients with head and neck cancer undergoing radiotherapy
Differentiation of irradiation and cetuximab induced skin reactions in patients with locally advanced head and neck cancer undergoing radioimmunotherapy: the HICARE protocol (Head and neck cancer: ImmunoChemo and Radiotherapy with Erbitux) – a multicenter phase IV trial
Impact of cetuximab plus cisplatin alone and cetuximab plus cisplatin and paclitaxel regimen on humanistic outcome in head and neck cancer